CD80 antibody (CD80)

Details for Product anti-CD80 Antibody No. ABIN1176847, Supplier: Log in to see
Antigen
  • B7
  • B7-1
  • B7.1
  • BB1
  • CD28LG
  • CD28LG1
  • LAB7
  • B71
  • Cd28l
  • Ly-53
  • Ly53
  • MIC17
  • TSA1
  • CD80 molecule
  • Cd80 molecule
  • CD80 antigen
  • CD80
  • Cd80
Alternatives
anti-Human CD80 antibody for Immunoprecipitation
Reactivity
Mouse (Murine)
456
285
49
11
11
6
3
3
2
2
1
Host
Rat
399
126
96
94
42
16
Clonality (Clone)
Monoclonal ()
Conjugate
This CD80 antibody is un-conjugated
71
70
53
40
19
17
16
15
10
7
7
6
6
6
6
6
6
6
6
5
5
5
5
4
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Application
Blocking Reagent (BR), Flow Cytometry (FACS)
508
220
171
153
115
101
81
42
40
26
22
22
12
8
7
6
6
5
5
5
2
2
2
2
1
1
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Brand BD Pharmingen™
Immunogen Activated Mouse 5C2 Cells
Clone 1G10-B7
Isotype IgG2a, kappa
Purification The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Sterility 0.2 μm filtered
Endotoxin Level Endotoxin level is ≤ 0.01 EU/μg (≤ 0.001 ng/μg) of protein as determined by the LAL assay.
Plasmids, Primers & others Plasmids, Primers & others CD80 products on genomics-online (e.g. as negative or positive controls)
Antigen
Alternative Name CD80 (CD80 Antibody Abstract)
Background The 1G10 antibody reacts with CD80 (B7-1). This member of the Ig superfamily, along with CD86 (B7-2), participates in T-cell costimulation via interactions with CD28 and CD152 (CTLA-4). CD80 is constitutively expressed on dendritic cells, monocytes, and peritoneal macrophages, and it is inducible on B cells by various means, including activation by LPS, IL-4, and the cross-linking of surface Ig. Expression of CD80 is greatly enhanced on splenic B cells following activation by LPS, with peak expression occurring between 48 and 72 hours. It has been reported that activation of purified B cells with LPS can induce CD80 expression in as few as 18 hours. The 1G10 antibody blocks binding of CTLA-4-Ig to CD80, but it does not block stimulation of T cells by natural antigen-presenting cells. Preliminary evidence has shown that mAb 16-10A1 (Cat. no. 553766) blocks binding of 1G10 mAb to CD80, indicating that the two antibodies may recognize overlapping epitopes on the CD80 molecule. However, the 16-10A1 mAb recognizes an upregulated antigen on UV-irradiated P815 mastocytoma cells which is not detected by the 1G10 mAb, the cause and significance of this differential reactivity of the two anti-CD80 antibodies is unknown.
Synonyms: B7-1
Pathways TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process
Application Notes Since this antigen is expressed at low density, it may be desirable to amplify staining by using a biotinylated second-step antibody followed by a “bright” third-step reagent, such as Streptavidin-PE (Cat. no. 554061). Other reported applications include blocking of ligand binding.
Restrictions For Research Use only
Concentration 1.0 mg/mL
Buffer No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2μm sterile filtered.
Preservative Azide free
Storage 4 °C
Storage Comment Store undiluted at 4°C. This preparation contains no preservatives, thus it should be handled under aseptic conditions.
Product cited in: Sojka, Donepudi, Bluestone, Mokyr: "Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 164, Issue 12, pp. 6230-6, 2000 (PubMed).

Boussiotis, Gribben, Freeman, Nadler: "Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance." in: Current opinion in immunology, Vol. 6, Issue 5, pp. 797-807, 1995 (PubMed).

Bluestone: "New perspectives of CD28-B7-mediated T cell costimulation." in: Immunity, Vol. 2, Issue 6, pp. 555-9, 1995 (PubMed).

Hathcock, Laszlo, Pucillo, Linsley, Hodes: "Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function." in: The Journal of experimental medicine, Vol. 180, Issue 2, pp. 631-40, 1994 (PubMed).

Nabavi, Freeman, Gault, Godfrey, Nadler, Glimcher: "Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression." in: Nature, Vol. 360, Issue 6401, pp. 266-8, 1992 (PubMed).